EN Official Journal of the European Union C 20/2

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2005 to 31 December 2005

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2006/C 20/02)

— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision Name of the medicinal product Holder of the marketing authorization Number of the entry in the Community Register Date of notification 23.12.2005 Kinzalkomb Bayer AG, D-51368 Leverkusen EU/1/02/214/001-010 29.12.2005 23.12.2005 PhotoBarr Axcan Pharma International BV, Engelenkampstraat 72, 6131 JJ Sittard, Nederland EU/1/04/272/001-002 28.12.2005 23.12.2005 Aptivus Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein EU/1/05/315/001 28.12.2005 23.12.2005 Avastin Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom EU/1/04/300/001-002 3.1.2006 23.12.2005 Stocrin Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom EU/1/99/111/001-009 3.1.2006 23.12.2005 Zometa Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom EU/1/01/176/001-006 3.1.2006 23.12.2005 Sustiva Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UD8 1DH, United Kingdom EU/1/99/110/001-009 3.1.2006 23.12.2005 Rilutek Aventis Pharma SA, 20 Avenue Raymond Aron, F-Antony Cedex 92165 EU/1/96/010/001 28.12.2005 23.12.2005 Revasc Canyon Pharmaceuticals Ltd, 20-22 Bedford Row, WC1R 4JS London, United Kingdom EU/1/97/043/001-003 3.1.2006 23.12.2005 Invirase Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom EU/1/96/026/001-002 3.1.2006 23.12.2005 Regranex Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse EU/1/99/101/001 2.1.2006 23.12.2005 MicardisPlus Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein EU/1/02/213/001-010 5.1.2006 23.12.2005 BeneFIX Wyeth Europa Ltd, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom EU/1/97/047/001-003 28.12.2005 23.12.2005 Fortovase Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom EU/1/98/075/001-002 3.1.2006 23.12.2005 Truvada Gilead Sciences International Limited, Granta Park Abington Cambridge CB1 6GT, United Kingdom EU/1/04/305/001 3.1.2006

— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision Name of the medicinal product Holder of the marketing authorization Number of the entry in the Community Register Date of notification 23.12.2005 Zubrin Schering-Plough Limited, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom EU/2/00/028/001-008 28.12.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency 7, Westferry Circus, Canary Wharf London E14 4HB United Kingdom

(1) OJ L 136, 30.4.2004, p. 1.